Brief report · 29 Dec 2025
Conference abstractPublished 27 Sep 2018
Serum IRAP, a novel direct biomarker of insulin-resistance as a screening, diagnostic and drug discovery tool
University Grenoble Alpes, France
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Insulin resistance (IR) affects more than half of the adult population worldwide. Type 2 diabetes (T2D), which often follows in the absence of treatment, affects more than 400 million people and represents more than 10 % of the health budget in industrialized countries. A preventive public health policy is urgently needed in order to stop this constantly progressing epidemic. Indeed, early management of IR does not only strongly reduce its evolution towards T2D but also strongly reduces the appearance of cardiovascular comorbidity as well as that of associated cancers. There is however currently no simple and reliable test available for the diagnosis or screening of IR. We therefore developed an ELISA for the quantitative determination of a novel circulating biomarker of IR, IRAP. IRAP is associated with and translocated in a stoechiometric fashion together with GLUT4 to the plasma membrane in response to insulin in skeletal muscle and adipose tissue. Its extracellular domain is subsequently cleaved and secreted in the blood stream. In T2D, IRAP translocation in response to insulin is strongly decreased. Our patented sandwich ELISA is highly sensitive and specific, robust and very cost-effective. Results of pilot studies indicate an excellent correlation between serum IRAP levels and insulin sensitivity. We therefore believe that serum IRAP is a direct marker of insulin sensitivity and that the quantitative determination of its plasma levels should allow large-scale screening of populations at risk for IR and T2D, thereby allowing the enforcement of a preventive health policy aiming at reducing this epidemic. Similarly, simple companion tests alowing the assessment of the efficacy of novel drugs aimed at improving insulin sensitivity do not exist yet. As such serum IRAP appears as a useful alternative to the euglycemic hyperinsulinic clamp which is very tedious, expensive and requires experencied teams, to monitor insulin sensitivity in human in clinical trials and therapeutic trials. Recent Publications 1. Insulin resistance (IR) affects more than half of the adult population worldwide. Type 2 diabetes (T2D), which often follows in the absence of treatment, affects more than 400 million people and represents more than 10 % of the health budget in industrialized countries. A preventive public health policy is urgently needed in order to stop this constantly progressing epidemic. Indeed, early management of IR does not only strongly reduce its evolution towards T2D but also strongly reduces the appearance of cardiovascular comorbidity as well as that of associated cancers. 2. There is however currently no simple and reliable test available for the diagnosis or screening of IR. We therefore developed an ELISA for the quantitative determination of a novel circulating biomarker of IR, IRAP. IRAP is associated with and translocated in a stoechiometric fashion together with GLUT4 to the plasma membrane in response to insulin in skeletal muscle and adipose tissue. Its extracellular domain is subsequently cleaved and secreted in the blood stream. In T2D, IRAP translocation in response to insulin is strongly decreased. 3. Our patented sandwich ELISA is highly sensitive and specific, robust and very cost-effective. Results of pilot studies indicate an excellent correlation between serum IRAP levels and insulin sensitivity. We therefore believe that serum IRAP is a direct marker of insulin sensitivity and that the quantitative determination of its plasma levels should allow large-scale screening of populations at risk for IR and T2D, thereby allowing the enforcement of a preventive health policy aiming at reducing this epidemic. 4. Similarly, simple companion tests alowing the assessment of the efficacy of novel drugs aimed at improving insulin sensitivity do not exist yet. As such serum IRAP appears as a useful alternative to the euglycemic hyperinsulinic clamp which is very tedious, expensive and requires experencied teams, to monitor insulin sensitivity in human in clinical trials and therapeutic trials.
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Diabetic Complications & Medicine.
Brief report · 29 Dec 2025
Diabetes Liver Toll: NAFLD to Cirrhosis
Opinion · 29 Dec 2025
Early Screening Crucial for Diabetic Complication Outcomes
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Diabetic Complications & Medicine
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Serge P Bottari”
